SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as the market reacts to the company's latest subscription price hikes, which analysts view as a strategic move to fund a massive content budget and solidify profitability. While some retail investors are voicing frustration over recurring cost increases, the community is heavily focused on the stock's relative strength and technical breakout potential, with many discussing its role as a hedge against broader market volatility.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is rallying as investors react to a strategic $14.2 billion deal to regain full ownership of its Ireland-based Fab 34, a move perceived as a major vote of confidence in the company's manufacturing and AI-driven growth trajectory. The community is actively debating the stock's future, with many interpreting the heavy capital reinvestment as a clear indicator that major new customer contracts are imminent.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is trending following the recent FDA approval of its rare disease drug, VYKAT XR, which has triggered intense market activity and discussions regarding the company's valuation, potential for a future buyout, and its ability to execute a successful commercial launch. Investors and traders are closely monitoring price action as the company transitions into a commercial-stage entity, with active debate surrounding its long-term growth prospects versus risks of dilution or volatility.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to heightened speculation surrounding a potential buyout, as market participants monitor recent biotech deal flow and comments from industry observers. While some investors focus on the company's robust obesity drug pipeline and late-stage clinical progress, others are actively debating the impact of competitive GLP-1 developments and broader macroeconomic volatility on its near-term valuation.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

The Next Bitcoin

Investors are rallying behind this Solana-based meme coin as a satirical movement intended to mock established market structures, with community members actively comparing its long-term potential to industry giants. Discussions are currently dominated by enthusiasts promoting the token's cultural narrative and its goal of creating viral engagement within the broader crypto ecosystem.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is trending as the market reacts to the definitive agreement to acquire Soleno Therapeutics for $2.9 billion. Community sentiment is mixed, with active debate regarding whether the acquisition effectively addresses Neurocrine's need for pipeline growth or if the premium paid for the rare-disease asset signals a strategic overpay.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is currently trending as shareholders analyze the strategic implications of parent company Centurium Capitals acquisition of Blue Bottle Coffee. While the community remains divided over potential conflicts of interest versus synergistic growth, investors are closely monitoring for signs of a long-anticipated U.S. exchange relisting and are actively debating the stock's future valuation amid shifting institutional ownership.

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group Inc.

Altria Group is seeing significant investor interest driven by a combination of resilient pricing power in its core smokeable business and ongoing momentum in its smoke-free portfolio, particularly with the growth of its on! nicotine pouches. The community is actively debating the company's long-term pivot from traditional cigarettes toward smoke-free alternatives, with many highlighting the stock's role as a classic, high-yield defensive play in a volatile market.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently facing significant volatility following analyst downgrades and concerns over its debt load, coupled with investor anxiety regarding negative free cash flow and strategic pivots. While some market participants are monitoring the stock for potential short-squeeze dynamics, the community is actively debating the sustainability of its business model versus the possibility of a recovery in travel-driven revenue.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

The ARK Innovation ETF is seeing heightened community activity as investors weigh its exposure to volatile tech and crypto-linked assets against recent selling trends by ARK leadership. Discussion is primarily centered on skepticism regarding the fund's long-term performance and active debate over whether current market conditions offer a value entry or a trap for speculative growth investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Brokers Issue Forecasts for ZNTL FY2030 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Zentalis Pharmaceuticals in a report released on...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen cut Zentalis Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...

Zentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reiterated at Guggenheim

Guggenheim reaffirmed a "buy" rating and issued a $6.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus...

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received a consensus rating of "Hold" from the six ratings firms that are covering the stock, MarketBeat reports. One research...

Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 25. (View Earnings Report at...

Wells Fargo & Company Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Wells Fargo & Company began coverage on Zentalis Pharmaceuticals in a research note on Tuesday. They issued an "equal weight" rating and a $5.00 price objective on the stock...

Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC

Almitas Capital LLC trimmed its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 71.4% during the third quarter, according to the company in its most recent 13F filing with...

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been assigned an average recommendation of "Hold" from the six research firms that are currently covering the stock, MarketBeat...

Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon

Zentalis Pharmaceuticals (NASDAQ:ZNTL) executives outlined a strategy centered on advancing its WEE1 inhibitor azenosertib toward potential approval in platinum-resistant ovarian cancer (PROC...

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

ZNTL
Zentalis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZNTL News

ZNTLZentalis Pharmaceuticals Inc